4/9
07:28 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
High
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
4/8
08:15 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $45.00 price target on the stock.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $45.00 price target on the stock.
4/4
04:05 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Medium
Report
Spyre Therapeutics Announces Grants of Inducement Awards
3/27
04:45 pm
syre
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody [Yahoo! Finance]
Low
Report
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody [Yahoo! Finance]
3/27
04:05 pm
syre
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
Low
Report
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
3/18
08:08 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $27.00 price target on the stock.
Medium
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $27.00 price target on the stock.
3/7
04:40 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Medium
Report
Spyre Therapeutics Announces Grants of Inducement Awards
2/27
04:05 pm
syre
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Medium
Report
Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2/25
08:16 am
syre
Spyre Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
Low
Report
Spyre Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
2/25
08:00 am
syre
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Low
Report
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
2/20
05:47 am
syre
Spyre Therapeutics, Inc. (NASDAQ: SYRE) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
Low
Report
Spyre Therapeutics, Inc. (NASDAQ: SYRE) was upgraded by analysts at The Goldman Sachs Group, Inc. to a "strong-buy" rating.
2/19
08:22 am
syre
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation [Yahoo! Finance]
Low
Report
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation [Yahoo! Finance]
2/19
08:00 am
syre
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
Low
Report
Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation
2/7
05:13 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Low
Report
Spyre Therapeutics Announces Grants of Inducement Awards
2/4
05:15 pm
syre
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
2/1
10:00 am
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
1/30
12:00 pm
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
1/28
12:10 pm
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
1/26
12:00 pm
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Medium
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
1/24
01:00 pm
syre
ATTENTION SYRE SHAREHOLDERS: Investors who Lost Money on Spyre Therapeutics, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
Low
Report
ATTENTION SYRE SHAREHOLDERS: Investors who Lost Money on Spyre Therapeutics, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
1/24
12:00 pm
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
1/23
11:00 am
syre
Lost Money on Spyre Therapeutics, Inc. (SYRE)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
Medium
Report
Lost Money on Spyre Therapeutics, Inc. (SYRE)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
1/22
03:45 pm
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
1/21
07:10 pm
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
Low
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
1/18
12:00 pm
syre
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE
High
Report
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE